메뉴 건너뛰기




Volumn 38, Issue 3, 2012, Pages 212-217

Activity and resistance of trastuzumab according to different clinical settings

Author keywords

Breast cancer; HER2; Resistance; Response to therapy; Trastuzumab

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

EID: 84857645689     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.06.002     Document Type: Review
Times cited : (34)

References (65)
  • 1
    • 73349085919 scopus 로고    scopus 로고
    • Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer
    • Spector N.L., Blackwell K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27:5838-5847.
    • (2009) J Clin Oncol , vol.27 , pp. 5838-5847
    • Spector, N.L.1    Blackwell, K.L.2
  • 2
    • 0037099532 scopus 로고    scopus 로고
    • Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action
    • Yakes F.M., Chinratanalab W., Ritter C.A., et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002, 62:4132-4141.
    • (2002) Cancer Res , vol.62 , pp. 4132-4141
    • Yakes, F.M.1    Chinratanalab, W.2    Ritter, C.A.3
  • 3
    • 0035874981 scopus 로고    scopus 로고
    • Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells
    • Molina M.A., Codony-Servat J., Albanell J., et al. Trastuzumab (herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001, 61:4744-4749.
    • (2001) Cancer Res , vol.61 , pp. 4744-4749
    • Molina, M.A.1    Codony-Servat, J.2    Albanell, J.3
  • 4
    • 0034076307 scopus 로고    scopus 로고
    • Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
    • Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446.
    • (2000) Nat Med , vol.6 , pp. 443-446
    • Clynes, R.A.1    Towers, T.L.2    Presta, L.G.3    Ravetch, J.V.4
  • 5
    • 70949095656 scopus 로고    scopus 로고
    • Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents
    • Boone J.J., Bhosle J., Tilby M.J., Hartley J.A., Hochhauser D. Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. Mol Cancer Ther 2009, 8:3015-3023.
    • (2009) Mol Cancer Ther , vol.8 , pp. 3015-3023
    • Boone, J.J.1    Bhosle, J.2    Tilby, M.J.3    Hartley, J.A.4    Hochhauser, D.5
  • 6
    • 2942659576 scopus 로고    scopus 로고
    • Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
    • Pegram M.D., Konecny G.E., O'Callaghan C., et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer I 2004, 96:739-749.
    • (2004) J Natl Cancer I , vol.96 , pp. 739-749
    • Pegram, M.D.1    Konecny, G.E.2    O'Callaghan, C.3
  • 7
    • 0036861177 scopus 로고    scopus 로고
    • Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria
    • Trillet-Lenoir V., Freyer G., Kaemmerlen P., et al. Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol 2002, 75:903-908.
    • (2002) Br J Radiol , vol.75 , pp. 903-908
    • Trillet-Lenoir, V.1    Freyer, G.2    Kaemmerlen, P.3
  • 8
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 9
    • 41449105551 scopus 로고    scopus 로고
    • HER2 status and benefit from adjuvant trastuzumab in breast cancer
    • Paik S., Kim C., Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008, 358:1409-1411.
    • (2008) N Engl J Med , vol.358 , pp. 1409-1411
    • Paik, S.1    Kim, C.2    Wolmark, N.3
  • 10
    • 33947594043 scopus 로고    scopus 로고
    • Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy
    • Agus D.B., Sweeney C.J., Morris M.J., et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 2007, 25:675-681.
    • (2007) J Clin Oncol , vol.25 , pp. 675-681
    • Agus, D.B.1    Sweeney, C.J.2    Morris, M.J.3
  • 11
    • 4444372733 scopus 로고    scopus 로고
    • Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2
    • Gennari R., Ménard S., Fagnoni F., et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004, 10:5650-5655.
    • (2004) Clin Cancer Res , vol.10 , pp. 5650-5655
    • Gennari, R.1    Ménard, S.2    Fagnoni, F.3
  • 12
    • 37549011436 scopus 로고    scopus 로고
    • Elements related to heterogeneity of antibody-dependent cell cytotoxicity (ADCC) in patients under trastuzumab therapy for primary operable breast cancer overexpressing HER2
    • Varchetta S., Gibelli N., Oliviero B., et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity (ADCC) in patients under trastuzumab therapy for primary operable breast cancer overexpressing HER2. Cancer Res 2007, 67:11991-11999.
    • (2007) Cancer Res , vol.67 , pp. 11991-11999
    • Varchetta, S.1    Gibelli, N.2    Oliviero, B.3
  • 13
    • 0036467826 scopus 로고    scopus 로고
    • Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
    • Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
    • (2002) J Clin Oncol , vol.20 , pp. 719-726
    • Vogel, C.L.1    Cobleigh, M.A.2    Tripathy, D.3
  • 14
    • 44949125431 scopus 로고    scopus 로고
    • Correlation between NK function and response to trastuzumab in metastatic breast cancer patients
    • Beano A., Signorino E., Evangelista A., et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 2008, 6:25.
    • (2008) J Transl Med , vol.6 , pp. 25
    • Beano, A.1    Signorino, E.2    Evangelista, A.3
  • 15
    • 51449102098 scopus 로고    scopus 로고
    • Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review
    • Madarnas Y., Trudeau M., Franek J.A., et al. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 2008, 34:539-557.
    • (2008) Cancer Treat Rev , vol.34 , pp. 539-557
    • Madarnas, Y.1    Trudeau, M.2    Franek, J.A.3
  • 16
    • 77951624086 scopus 로고    scopus 로고
    • Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
    • Untch M., Rezai M., Loibl S., et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010, 28:2024-2031.
    • (2010) J Clin Oncol , vol.28 , pp. 2024-2031
    • Untch, M.1    Rezai, M.2    Loibl, S.3
  • 17
    • 76949095183 scopus 로고    scopus 로고
    • Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer
    • Chumsri S., Jeter S., Jacobs L.K., et al. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. Clin Breast Cancer 2010, 10:40-45.
    • (2010) Clin Breast Cancer , vol.10 , pp. 40-45
    • Chumsri, S.1    Jeter, S.2    Jacobs, L.K.3
  • 18
    • 20544460650 scopus 로고    scopus 로고
    • Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
    • Buzdar A.U., Ibrahim N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23:3676-3685.
    • (2005) J Clin Oncol , vol.23 , pp. 3676-3685
    • Buzdar, A.U.1    Ibrahim, N.K.2    Francis, D.3
  • 19
    • 75149145066 scopus 로고    scopus 로고
    • Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
    • Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
    • (2010) Lancet , vol.375 , pp. 377-384
    • Gianni, L.1    Eiermann, W.2    Semiglazov, V.3
  • 20
    • 77951204959 scopus 로고    scopus 로고
    • Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancer
    • Iorfida M., Bagnardi V., Balduzzi A., et al. Preoperative therapy with trastuzumab and oral vinorelbine (+/- endocrine therapy) in patients with HER2-positive breast cancer. Breast 2010, 19:128-132.
    • (2010) Breast , vol.19 , pp. 128-132
    • Iorfida, M.1    Bagnardi, V.2    Balduzzi, A.3
  • 21
    • 58249103214 scopus 로고    scopus 로고
    • Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists
    • Mosley J.D., Keri R.A. Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. BMC Med Genomics 2008, 1:11.
    • (2008) BMC Med Genomics , vol.1 , pp. 11
    • Mosley, J.D.1    Keri, R.A.2
  • 22
    • 34347332446 scopus 로고    scopus 로고
    • NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy
    • Mozaffari F., Lindemalm C., Choudhury A., et al. NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. Br J Cancer 2007, 97:105-111.
    • (2007) Br J Cancer , vol.97 , pp. 105-111
    • Mozaffari, F.1    Lindemalm, C.2    Choudhury, A.3
  • 23
    • 0028200221 scopus 로고
    • Antibody to her-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
    • Pietras R.J., Fendly B.M., Chazin V.R., et al. Antibody to her-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994, 9:1829-1838.
    • (1994) Oncogene , vol.9 , pp. 1829-1838
    • Pietras, R.J.1    Fendly, B.M.2    Chazin, V.R.3
  • 24
    • 0032578797 scopus 로고    scopus 로고
    • Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
    • Pietras R.J., Pegram M.D., Finn R.S., Maneval D.A., Slamon D.J. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998, 17:2235-2249.
    • (1998) Oncogene , vol.17 , pp. 2235-2249
    • Pietras, R.J.1    Pegram, M.D.2    Finn, R.S.3    Maneval, D.A.4    Slamon, D.J.5
  • 25
    • 45749086163 scopus 로고    scopus 로고
    • Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer
    • Bullock K., Blackwell K. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist 2008, 13:515-525.
    • (2008) Oncologist , vol.13 , pp. 515-525
    • Bullock, K.1    Blackwell, K.2
  • 26
    • 33846468746 scopus 로고    scopus 로고
    • Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms
    • Legrier M.E., Oudard S., Judde J.G., et al. Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer 2007, 96:269-276.
    • (2007) Br J Cancer , vol.96 , pp. 269-276
    • Legrier, M.E.1    Oudard, S.2    Judde, J.G.3
  • 27
    • 26844503270 scopus 로고    scopus 로고
    • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    • Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
    • (2005) N Engl J Med , vol.353 , pp. 1659-1672
    • Piccart-Gebhart, M.J.1    Procter, M.2    Leyland-Jones, B.3
  • 28
    • 36148961294 scopus 로고    scopus 로고
    • Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer (abstract 512)
    • Perez E.A., Romond E.H., Suman V.J., et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer (abstract 512). J Clin Oncol 2007, 25S.
    • (2007) J Clin Oncol
    • Perez, E.A.1    Romond, E.H.2    Suman, V.J.3
  • 29
    • 76949091692 scopus 로고    scopus 로고
    • Results of chemotherapy alone, with sequential or concurrent addition of 52weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial
    • [suppl; abstr. 701]
    • Perez E.A., Suman V.J., Davidson N.E. Results of chemotherapy alone, with sequential or concurrent addition of 52weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial. Cancer Res 2009, 69:24. [suppl; abstr. 701].
    • (2009) Cancer Res , vol.69 , pp. 24
    • Perez, E.A.1    Suman, V.J.2    Davidson, N.E.3
  • 30
    • 60849094827 scopus 로고    scopus 로고
    • Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer
    • Bedard P.L., Piccart-Gebhart M.J. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin Breast Cancer 2008, 8:S157-S165.
    • (2008) Clin Breast Cancer , vol.8
    • Bedard, P.L.1    Piccart-Gebhart, M.J.2
  • 31
    • 77955291428 scopus 로고    scopus 로고
    • Sequential or concurrent administration of trastuzumab in early breast cancer? Too early to judge
    • Azim H.A., De Azambuja E., Paesmans M., Piccart-Gebhart M.J. Sequential or concurrent administration of trastuzumab in early breast cancer? Too early to judge. J Clin Oncol 2010, 28:e353-e354.
    • (2010) J Clin Oncol , vol.28
    • Azim, H.A.1    De Azambuja, E.2    Paesmans, M.3    Piccart-Gebhart, M.J.4
  • 32
    • 84869206521 scopus 로고    scopus 로고
    • Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better
    • [Epub ahead of print]
    • Petrelli F., Barni S. Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better. Med Oncol 2011, [Epub ahead of print].
    • (2011) Med Oncol
    • Petrelli, F.1    Barni, S.2
  • 33
    • 74949141693 scopus 로고    scopus 로고
    • Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial
    • Spielmann M., Roche H., Delozier T., et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009, 27:6129-6134.
    • (2009) J Clin Oncol , vol.27 , pp. 6129-6134
    • Spielmann, M.1    Roche, H.2    Delozier, T.3
  • 34
    • 33845914783 scopus 로고    scopus 로고
    • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
    • Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
    • (2007) Lancet , vol.369 , pp. 29-36
    • Smith, I.1    Procter, M.2    Gelber, R.D.3
  • 35
    • 54349107362 scopus 로고    scopus 로고
    • on behalf of the Demetra Group. Observational Demetra study: survival of metastatic breast carcinoma patients after treatment with trastuzumab. ASCO Annual Meeting Proceedings 26, Abstract 1062
    • Ménard S, on behalf of the Demetra Group. Observational Demetra study: survival of metastatic breast carcinoma patients after treatment with trastuzumab. J. Clin. Oncol. ASCO Annual Meeting Proceedings 26, Abstract 1062; 2008.
    • (2008) J. Clin. Oncol
    • Ménard, S.1
  • 36
    • 65349110371 scopus 로고    scopus 로고
    • Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study
    • Von Minckwitz G., Dubois A., Schmidt M., et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009, 27:1999-2006.
    • (2009) J Clin Oncol , vol.27 , pp. 1999-2006
    • Von Minckwitz, G.1    Dubois, A.2    Schmidt, M.3
  • 37
    • 65849322821 scopus 로고    scopus 로고
    • Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer
    • Cancello G., Montagna E., D'Agostino D., et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res 2008, 10:R60.
    • (2008) Breast Cancer Res , vol.10
    • Cancello, G.1    Montagna, E.2    D'Agostino, D.3
  • 38
    • 77949884661 scopus 로고    scopus 로고
    • Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer
    • Blackwell K.L., Burstein H.J., Storniolo A.M., et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.
    • (2010) J Clin Oncol , vol.28 , pp. 1124-1130
    • Blackwell, K.L.1    Burstein, H.J.2    Storniolo, A.M.3
  • 39
    • 79959226810 scopus 로고    scopus 로고
    • Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study
    • Campiglio M., Bufalino R., Sandri M., et al. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res Treat 2011, 128:147-154.
    • (2011) Breast Cancer Res Treat , vol.128 , pp. 147-154
    • Campiglio, M.1    Bufalino, R.2    Sandri, M.3
  • 40
    • 77950638130 scopus 로고    scopus 로고
    • Roche plans for more convenient-to-use Herceptin and Rituxan
    • Ratner M. Roche plans for more convenient-to-use Herceptin and Rituxan. Nat Biotechnol 2010, 28:298.
    • (2010) Nat Biotechnol , vol.28 , pp. 298
    • Ratner, M.1
  • 41
    • 23844549918 scopus 로고    scopus 로고
    • Breast cancer molecular subtypes respond differently to preoperative chemotherapy
    • Rouzier R., Perou C.M., Symmans W.F., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685.
    • (2005) Clin Cancer Res , vol.11 , pp. 5678-5685
    • Rouzier, R.1    Perou, C.M.2    Symmans, W.F.3
  • 42
    • 28044472321 scopus 로고    scopus 로고
    • Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer
    • Gianni L., Zambetti M., Clark K., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005, 23:7265-7277.
    • (2005) J Clin Oncol , vol.23 , pp. 7265-7277
    • Gianni, L.1    Zambetti, M.2    Clark, K.3
  • 43
    • 62449131093 scopus 로고    scopus 로고
    • Supervised risk predictor of breast cancer based on intrinsic subtypes
    • Parker J.S., Mullins M., Cheang M.C., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167.
    • (2009) J Clin Oncol , vol.27 , pp. 1160-1167
    • Parker, J.S.1    Mullins, M.2    Cheang, M.C.3
  • 44
    • 0036707703 scopus 로고    scopus 로고
    • Ki-67 immunostaining activity is higher in positive axillary lymph nodes than in the primary breast tumor
    • Buxant F., Anaf V., Simon P., Fayt I., Noel J.C. Ki-67 immunostaining activity is higher in positive axillary lymph nodes than in the primary breast tumor. Breast Cancer Res Treat 2002, 75:1-3.
    • (2002) Breast Cancer Res Treat , vol.75 , pp. 1-3
    • Buxant, F.1    Anaf, V.2    Simon, P.3    Fayt, I.4    Noel, J.C.5
  • 45
    • 33750470093 scopus 로고    scopus 로고
    • Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients
    • Calascibetta A., Cabibi D., Rausa L., et al. Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients. Nucleosides Nucleotides Nucleic Acids 2006, 25:1193-1196.
    • (2006) Nucleosides Nucleotides Nucleic Acids , vol.25 , pp. 1193-1196
    • Calascibetta, A.1    Cabibi, D.2    Rausa, L.3
  • 46
    • 2542526069 scopus 로고    scopus 로고
    • P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells
    • Nahta R., Takahashi T., Ueno N.T., Hung M.C., Esteva F.J. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004, 64:3981-3986.
    • (2004) Cancer Res , vol.64 , pp. 3981-3986
    • Nahta, R.1    Takahashi, T.2    Ueno, N.T.3    Hung, M.C.4    Esteva, F.J.5
  • 47
    • 35148885729 scopus 로고    scopus 로고
    • A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
    • Berns K., Horlings H.M., Hennessy B.T., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
    • (2007) Cancer Cell , vol.12 , pp. 395-402
    • Berns, K.1    Horlings, H.M.2    Hennessy, B.T.3
  • 48
    • 31444444131 scopus 로고    scopus 로고
    • PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
    • Fujita T., Doihara H., Kawasaki K., et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 2006, 94:247-252.
    • (2006) Br J Cancer , vol.94 , pp. 247-252
    • Fujita, T.1    Doihara, H.2    Kawasaki, K.3
  • 49
    • 33748159249 scopus 로고    scopus 로고
    • Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells
    • Fujita T., Doihara H., Washio K., et al. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells. Anticancer Drugs 2006, 17:455-462.
    • (2006) Anticancer Drugs , vol.17 , pp. 455-462
    • Fujita, T.1    Doihara, H.2    Washio, K.3
  • 50
    • 35348917266 scopus 로고    scopus 로고
    • Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency
    • Lu C.H., Wyszomierski S.L., Tseng L.M., et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 2007, 13:5883-5888.
    • (2007) Clin Cancer Res , vol.13 , pp. 5883-5888
    • Lu, C.H.1    Wyszomierski, S.L.2    Tseng, L.M.3
  • 51
    • 5144226211 scopus 로고    scopus 로고
    • PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
    • Nagata Y., Lan K.H., Zhou X., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
    • (2004) Cancer Cell , vol.6 , pp. 117-127
    • Nagata, Y.1    Lan, K.H.2    Zhou, X.3
  • 52
    • 77950617839 scopus 로고    scopus 로고
    • Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
    • Fabi A., Metro G., Di Benedetto A., et al. Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Oncology 2010, 78:141-149.
    • (2010) Oncology , vol.78 , pp. 141-149
    • Fabi, A.1    Metro, G.2    Di Benedetto, A.3
  • 53
    • 0036606779 scopus 로고    scopus 로고
    • The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides
    • Motoyama A.B., Hynes N.E., Lane H.A. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 2002, 62:3151-3158.
    • (2002) Cancer Res , vol.62 , pp. 3151-3158
    • Motoyama, A.B.1    Hynes, N.E.2    Lane, H.A.3
  • 54
    • 69049096137 scopus 로고    scopus 로고
    • A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab
    • Mani A., Roda J., Young D., et al. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat 2009, 117:83-89.
    • (2009) Breast Cancer Res Treat , vol.117 , pp. 83-89
    • Mani, A.1    Roda, J.2    Young, D.3
  • 55
    • 0041496974 scopus 로고    scopus 로고
    • CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations
    • Van Ojik H.H., Bevaart L., Dahle C.E., et al. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res 2003, 63:5595-5600.
    • (2003) Cancer Res , vol.63 , pp. 5595-5600
    • Van Ojik, H.H.1    Bevaart, L.2    Dahle, C.E.3
  • 56
    • 37249026830 scopus 로고    scopus 로고
    • NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma
    • Moga E., Alvarez E., Canto E., et al. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp Hematol 2008, 36:69-77.
    • (2008) Exp Hematol , vol.36 , pp. 69-77
    • Moga, E.1    Alvarez, E.2    Canto, E.3
  • 57
    • 76349088256 scopus 로고    scopus 로고
    • Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma
    • Watanabe M., Kono K., Kawaguchi Y., et al. Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. Br J Cancer 2010, 102:520-529.
    • (2010) Br J Cancer , vol.102 , pp. 520-529
    • Watanabe, M.1    Kono, K.2    Kawaguchi, Y.3
  • 58
    • 63349086603 scopus 로고    scopus 로고
    • Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells
    • Levy E.M., Sycz G., Arriaga J.M., et al. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. Innate Immun 2009, 15:91-100.
    • (2009) Innate Immun , vol.15 , pp. 91-100
    • Levy, E.M.1    Sycz, G.2    Arriaga, J.M.3
  • 59
    • 67650895868 scopus 로고    scopus 로고
    • Mechanisms of escape from trastuzumab-mediated ADCC in esophageal squamous cell carcinoma: relation to susceptibility to perforin-granzyme
    • Kawaguchi Y., Kono K., Mizukami Y., Mimura K., Fujii H. Mechanisms of escape from trastuzumab-mediated ADCC in esophageal squamous cell carcinoma: relation to susceptibility to perforin-granzyme. Anticancer Res 2009, 29:2137-2146.
    • (2009) Anticancer Res , vol.29 , pp. 2137-2146
    • Kawaguchi, Y.1    Kono, K.2    Mizukami, Y.3    Mimura, K.4    Fujii, H.5
  • 60
    • 33746290773 scopus 로고    scopus 로고
    • Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation
    • Anido J., Scaltriti M., Bech Serra J.J., et al. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 2006, 25:3234-3244.
    • (2006) EMBO J , vol.25 , pp. 3234-3244
    • Anido, J.1    Scaltriti, M.2    Bech Serra, J.J.3
  • 61
    • 34247588567 scopus 로고    scopus 로고
    • Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
    • Scaltriti M., Rojo F., Ocana A., et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer I 2007, 99:628-638.
    • (2007) J Natl Cancer I , vol.99 , pp. 628-638
    • Scaltriti, M.1    Rojo, F.2    Ocana, A.3
  • 62
    • 33845364233 scopus 로고    scopus 로고
    • Cancer stem cells and oncology therapeutics
    • Al-Hajj M. Cancer stem cells and oncology therapeutics. Curr Opin Oncol 2007, 19:61-64.
    • (2007) Curr Opin Oncol , vol.19 , pp. 61-64
    • Al-Hajj, M.1
  • 63
    • 54049096261 scopus 로고    scopus 로고
    • HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion
    • Korkaya H., Paulson A., Iovino F., Wicha M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 1-11.
    • (2008) Oncogene , pp. 1-11
    • Korkaya, H.1    Paulson, A.2    Iovino, F.3    Wicha, M.S.4
  • 64
    • 62549096930 scopus 로고    scopus 로고
    • Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to Trastuzumab
    • Magnifico A., Albano L., Campaner S., et al. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to Trastuzumab. Clin Cancer Res 2009, 15:2010-2021.
    • (2009) Clin Cancer Res , vol.15 , pp. 2010-2021
    • Magnifico, A.1    Albano, L.2    Campaner, S.3
  • 65
    • 77649270350 scopus 로고    scopus 로고
    • Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling
    • Nakanishi T., Chumsri S., Khakpour N., et al. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer 2010, 102:815-826.
    • (2010) Br J Cancer , vol.102 , pp. 815-826
    • Nakanishi, T.1    Chumsri, S.2    Khakpour, N.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.